CN101669998B - Corydalis saxicola pill and preparation method thereof - Google Patents
Corydalis saxicola pill and preparation method thereof Download PDFInfo
- Publication number
- CN101669998B CN101669998B CN2009101926637A CN200910192663A CN101669998B CN 101669998 B CN101669998 B CN 101669998B CN 2009101926637 A CN2009101926637 A CN 2009101926637A CN 200910192663 A CN200910192663 A CN 200910192663A CN 101669998 B CN101669998 B CN 101669998B
- Authority
- CN
- China
- Prior art keywords
- yanhuanglian
- litectin
- pills
- extract
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000006187 pill Substances 0.000 title claims abstract description 100
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 241000783421 Corydalis saxicola Species 0.000 title description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 65
- 239000000284 extract Substances 0.000 claims abstract description 46
- 229930013930 alkaloid Natural products 0.000 claims abstract description 31
- 239000011347 resin Substances 0.000 claims abstract description 24
- 229920005989 resin Polymers 0.000 claims abstract description 24
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 20
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 20
- 239000007864 aqueous solution Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 239000003480 eluent Substances 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 10
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims description 10
- 239000012141 concentrate Substances 0.000 claims description 9
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 5
- 229940057995 liquid paraffin Drugs 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- -1 collect the eluate Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims 1
- 238000007493 shaping process Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 10
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 14
- 238000000576 coating method Methods 0.000 description 12
- 239000011248 coating agent Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 238000010828 elution Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000001179 sorption measurement Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 235000008504 concentrate Nutrition 0.000 description 6
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000011435 rock Substances 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000008118 PEG 6000 Substances 0.000 description 4
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 4
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000006356 dehydrogenation reaction Methods 0.000 description 2
- 239000012738 dissolution medium Substances 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 241000037740 Coptis chinensis Species 0.000 description 1
- 241000876833 Emberizinae Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000003181 co-melting Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940051810 licorice root extract Drugs 0.000 description 1
- 235000020725 licorice root extract Nutrition 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000006068 polycondensation reaction Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
岩黄连滴丸及其制备方法,涉及一种以岩黄连药材为原料,主治肝脏等疾病的中成药及其制备方法。岩黄连滴丸,是由岩黄连提取物1份,聚乙二醇4~6份制成。岩黄连提取物是采用岩黄连药材用50~70%的乙醇水溶液提取后所得提取物经大孔树脂吸附,用50~70%乙醇水溶液洗脱,洗脱液浓缩干燥所得的干品,干品重量中含岩黄连总碱55%以上,其中脱氢卡维汀占岩黄连提取物干品重量的10%以上。每克岩黄连滴丸中含岩黄连总生物碱85~135mg;含脱氢卡维汀18~45mg。该产品具有生物利用度高的优点,是能发挥高效、速效的口服制剂;滴丸制剂的生产工艺、生产设备简单,生产周期短,生产效率高,成本低等优点。
The Yanhuanglian dripping pill and a preparation method thereof relate to a Chinese patent medicine which takes the Yanhuanglian medicinal material as a raw material and mainly treats diseases such as the liver, and a preparation method thereof. Yanhuanglian dripping pills are made from 1 part of Yanhuanglian extract and 4-6 parts of polyethylene glycol. Yanhuanglian extract is the dry product obtained by extracting the medicinal material of Yanhuanglian with 50-70% ethanol aqueous solution, which is absorbed by macroporous resin, eluted with 50-70% ethanol aqueous solution, and the eluent is concentrated and dried. The weight contains more than 55 percent of the total alkaloids of the rhizome, and the dehydrocarvetine accounts for more than 10 percent of the weight of the dry product of the rhizome extract. Each gram of Yanhuanglian dripping pills contains 85-135 mg of total alkaloids of Yanhuanglian; 18-45 mg of dehydrocarvetine. The product has the advantages of high bioavailability and is an oral preparation capable of exerting high-efficiency and quick-acting effects; the production process and equipment of the dropping pill preparation are simple, the production cycle is short, the production efficiency is high, and the cost is low.
Description
技术领域technical field
本发明涉及一种以植物为原料,主治肝脏等疾病的中成药及其制备方法,具体是以岩黄连药材为原料制成的滴丸及其制备方法。The invention relates to a Chinese patent medicine which takes plants as raw materials and mainly treats diseases such as the liver and a preparation method thereof, in particular to a dripping pill made of rock rhizoma rhizomes as a raw material and a preparation method thereof.
背景技术Background technique
岩黄连系罂粟科紫堇属多年生草本植物石生黄堇Corydalis saxicolaBunting的干燥全草。本品性凉味苦,具有清热解毒、利湿止痛、散瘀消肿等功能,主治肝炎、肝硬化、肝癌、热毒痈疮、急性腹痛等疾病。Rock yellow is the dry whole plant of the perennial herbaceous plant Corydalis saxicola Bunting in the family Papaveraceae. This product is cool and bitter in taste, has the functions of clearing heat and detoxifying, promoting dampness and relieving pain, dispelling blood stasis and reducing swelling, etc.
目前,岩黄连的制剂只有注射液针剂面市,如广西河丰药业有限责任公司生产的岩黄连注射液,国药准字Z20046725,规格:每支装2mL,含岩黄连碱(也称脱氢卡维汀)0.7mg,采用静滴方式给药,但是岩黄连注射液在临床使用中,有报道指出其可导致个别过敏反应,表现为用药后周身瘙痒、心慌、寒战、发热,偶见恶心、呕吐等。At present, the preparations of Yanhuanglian are only available in injection injections, such as Yanhuanglian injection produced by Guangxi Hefeng Pharmaceutical Co., Ltd., Z20046725, specifications: 2mL per tube, containing lithosine Vitin) 0.7mg, administered by intravenous infusion, but Yanhuanglian Injection has been reported to cause individual allergic reactions in clinical use, manifested as itching, palpitation, chills, fever, and occasionally nausea, vomiting etc.
CN1453277A也公开了一种岩黄连总碱及其制备方法和应用,也公开了岩黄连采用有机溶剂提取后、经酸溶碱沉再用大孔树脂纯化精制的方法,并公开了将提取物制备成胶囊剂、颗粒剂,口服液和片剂的实施例,但该专利所说的岩黄连提取物中的岩黄连总碱的含量仅50%,脱氢卡维汀的含量仅为6.8%,且制备工艺复杂,所制备的口服制剂生物利用度较低。CN1453277A also discloses a total alkaloid of Litectin and its preparation method and application. It also discloses that Litectin is extracted with an organic solvent, then purified by acid-dissolving and alkali-precipitating, and then purified with macroporous resin, and discloses the preparation of the extract Capsules, granules, oral liquids and tablets, but the content of the total alkaloids of Litectin in the extract of the said patent is only 50%, and the content of dehydrocarvetine is only 6.8%. Moreover, the preparation process is complicated, and the bioavailability of the prepared oral preparation is low.
为此,有必要研制具有生物利用度高、快速释药、快速显效,毒副作用小的口服制剂,并改进岩黄连提取物的制备方法,使方法更简便,有效成分岩黄连总碱及脱氢卡维汀的含量更高。For this reason, it is necessary to develop an oral preparation with high bioavailability, rapid drug release, rapid effect, and small toxic and side effects, and improve the preparation method of the extract of Litectin, make the method easier, and the active ingredients Litectin total alkaloids and dehydrogenation Carvitin is even higher.
发明内容Contents of the invention
本发明的目的在于弥补现有技术的不足,提供一种生物利用度高,快速释药,快速显效,制剂中岩黄连的有效成分含量高,且临床使用和携带方便的岩黄连滴丸及其制备方法。The object of the present invention is to make up for the deficiencies of the prior art, to provide a kind of Yanhuanglian dripping pills and its preparations with high bioavailability, fast drug release, rapid effect, high active ingredient content of Yanhuanglian in the preparation, and convenient clinical use and portability. Preparation.
为达到本发明目的所采用的技术方案:岩黄连滴丸,是由以下重量份的原料制成To achieve the technical solution adopted for the purpose of the present invention: Yanhuanglian dripping pills are made from the raw materials of the following parts by weight
岩黄连提取物 1份Litectin extract 1 part
聚乙二醇 4~6份4-6 parts of polyethylene glycol
所述的岩黄连提取物是采用岩黄连药材用50~70%(V/V)的乙醇水溶液提取后所得提取物经大孔树脂吸附,用50~70%(V/V)乙醇水溶液洗脱,洗脱液浓缩干燥所得的干品,干品重量中含岩黄连总碱55%(W/W)以上,其中岩黄连总碱中的脱氢卡维汀(又称岩黄连碱)占岩黄连提取物干品重量的10%(W/W)以上,The extract of Litectin Rhizoma is extracted with 50-70% (V/V) aqueous ethanol solution of Litectin Rhizoma, and the obtained extract is adsorbed by macroporous resin and eluted with 50-70% (V/V) aqueous ethanol , the dry product obtained by concentrating and drying the eluent contains more than 55% (W/W) of total alkaloids of rhizome in the dry product weight, wherein dehydrocarvetine (also known as alkaloids of rhizome) in total alkaloids of rhizomes accounts for More than 10% (W/W) of the dry product weight of Coptis chinensis extract,
所述的岩黄连滴丸,每克滴丸中含岩黄连总生物碱80~135mg;每克滴丸中含脱氢卡维汀18~45mg。The Yanhuanglian dropping pills contain 80-135 mg of total alkaloids of Yanhuanglian per gram of the dropping pills, and 18-45 mg of dehydrocarvetine per gram of the dropping pills.
所述的聚乙二醇可优选分子量为4000或/和分子量为6000的聚乙二醇,聚乙二醇4000∶聚乙二醇6000的重量比为5~0∶0~5,且优选聚乙二醇4000∶聚乙二醇6000的重量比为4∶1或3∶2或1∶1,尤以聚乙二醇4000∶聚乙二醇6000的重量比为4∶1为最佳。The polyethylene glycol may preferably have a molecular weight of 4000 or/and a molecular weight of 6000, and the weight ratio of polyethylene glycol 4000: polyethylene glycol 6000 is 5-0: 0-5, and preferably polyethylene glycol The weight ratio of ethylene glycol 4000: polyethylene glycol 6000 is 4:1 or 3:2 or 1:1, especially the weight ratio of polyethylene glycol 4000: polyethylene glycol 6000 is 4:1.
本发明所提供的岩黄连滴丸的制备方法,是按以下步骤进行:The preparation method of Yanhuanglian dripping pills provided by the present invention is carried out in the following steps:
步骤一 岩黄连提取物的制备:取岩黄连药材,每次用6~10倍50~70%(V/V)乙醇水溶液回流1~3次,每次1-2小时,合并提取液,减压回收乙醇后浓缩至体积为岩黄连药材投料重量的5倍(即投料1公斤的岩黄连药材,浓缩液为5立升),将该溶液过滤,取滤液用大孔树脂吸附,用50~70%(V/V)乙醇水溶液洗脱,收集洗脱液、浓缩、干燥得到岩黄连提取物;Step 1: Preparation of Litectin Rhizoma Extract: Take Litectin Rhizoma Radix, reflux 1-3 times with 6-10 times 50-70% (V/V) ethanol aqueous solution each time, 1-2 hours each time, combine extracts, reduce After recovering ethanol, concentrate to a volume that is 5 times of the weight of the Radix Rhizoma medicinal material (that is, feed 1 kilogram of Radix Rhizoma Rhizoma Medicinal Material, and the concentrated solution is 5 liters), filter the solution, and get the filtrate to absorb with macroporous resin. 70% (V/V) ethanol aqueous solution was used for elution, and the eluate was collected, concentrated, and dried to obtain the extract of Litectin Rhizoma;
步骤二 配料:按岩黄连提取物∶聚乙二醇重量比为1∶4~6的比例,分别称取岩黄连提取物和聚乙二醇,先将聚乙二醇加热至熔融,搅拌下加入岩黄连提取物,混匀得到混合液;
步骤三 滴制:将混合液加入于滴丸机的滴制装置内,通过滴头滴入冷凝液中,调整滴丸机的温度控制系统,滴丸机的滴头温度保持在80±10℃,冷凝液的温度保持在0±5℃,冷凝液是液体石蜡或甲基硅油;Step 3 Dropping: Add the mixed liquid into the dripping device of the dropping pill machine, drop it into the condensate through the dropper, adjust the temperature control system of the dropping pill machine, and keep the dropper temperature of the dropping pill machine at 80±10°C , the temperature of the condensate is kept at 0±5°C, and the condensate is liquid paraffin or methyl silicone oil;
步骤四 擦丸:取出药丸,除去表面冷凝液,干燥即得素滴丸。Step 4 Wipe the pills: Take out the pills, remove the condensed liquid on the surface, and dry to get the Su dropping pills.
在岩黄连提取物精制时采用大孔树脂吸附分离的方法成本低,但不同型号的大孔树脂对不同的物质分离不同的成分有不同的结果,对于本发明的岩黄连提取物可优选用型号为HP-20、D101或D201的大孔树脂,其中以D101型大孔树脂为最佳。Adopting the method cost of macroporous resin adsorption separation when the extract of Litectin Rhizoma is refined is low; It is HP-20, D101 or D201 macroporous resin, among which D101 type macroporous resin is the best.
为了适合临床需要干燥成型后的素滴丸,可再用常规的工艺进行包糖衣层或包薄膜衣层制成包衣滴丸。In order to meet the clinical needs of the dried and shaped plain dropping pills, the conventional technology can be used to coat the sugar-coated layer or the film-coated layer to make the coated dripping pills.
有益效果 本发明所涉及的岩黄连滴丸,选用水溶性基质聚乙二醇,药物与基质共熔后可在骤冷的条件下形成固体分散体,药物以分子或无定型微粒状态存在,亲水性基质聚乙二醇对药物具有润湿作用,能使药物迅速溶散成微粒或溶液,因而使难溶性药物的溶解和吸收加快,从而提高了生物利用度,发挥高效、速效作用等;滴丸制剂的生产工艺、生产设备简单,生产周期短,生产效率高,成本低;岩黄连提取物中有效成分的含量高,岩黄连提取物的干品重量中含岩黄连总碱55%(W/W)以上,其中岩黄连总碱中的脱氢卡维汀在岩黄连提取物干品重量占10%(W/W)以上,且在滴丸制剂中有效成分的含量也较高,每克滴丸中含岩黄连总生物碱80~135mg;每克滴丸中含脱氢卡维汀18~45mg。Beneficial effects Yanhuanglian dripping pills involved in the present invention use polyethylene glycol as a water-soluble matrix, and the drug and the matrix can form a solid dispersion under quenching conditions after co-melting. The drug exists in the state of molecules or amorphous particles, which The water-based matrix polyethylene glycol has a wetting effect on the drug, which can quickly dissolve the drug into particles or solutions, thereby accelerating the dissolution and absorption of insoluble drugs, thereby improving the bioavailability and exerting high-efficiency and quick-acting effects; The production technology of the drop pill preparation, the production equipment are simple, the production cycle is short, the production efficiency is high, and the cost is low; the content of active ingredients in the extract of Litectin Rhizoma is high, and the dry product weight of Radix Rhizoma Rhizoma contains 55% ( W/W) or more, wherein the dehydrocarvetine in the total alkaloids of Litectin Rhizoma accounts for more than 10% (W/W) in dry product weight of Litectin Rhizoma, and the content of active ingredients in the dropping pill preparation is also higher, Each gram of drop pills contains 80-135 mg of total alkaloids of Litectin chinensis; each gram of drop pills contains 18-45 mg of dehydrocarvetine.
附图说明Description of drawings
图1 位岩黄连滴丸和片剂在大鼠体内平均药时曲线(n=6)图图中 1为岩黄连滴丸的药时曲线 2为岩黄连片剂的药时曲线Figure 1 The average drug-time curves of Yanhuanglian dripping pills and tablets in rats (n=6) In the figure, 1 is the drug-time curve of Yanhuanglian dripping pills, and 2 is the drug-time curve of Yanhuanglian tablets
下面结合实施例和试验例进一步阐述本发明的技术方案和有益效果,但不受实施例限制。The technical solutions and beneficial effects of the present invention are further described below in conjunction with examples and test examples, but are not limited by the examples.
具体实施方式Detailed ways
实施例1 滴丸的制备The preparation of embodiment 1 dropping pill
步骤一 岩黄连提取物的制备:取岩黄连药材1Kg,每次用8L的60%(V/V)乙醇回流3次,每次1.5小时,合并提取液,减压回收乙醇后浓缩至药液体积为5L,过滤,将滤液作为D101大孔树脂上样液,再用3倍柱体积的60%乙醇洗脱,收集洗脱液,浓缩,干燥,得到岩黄连提取物52g,用紫外分光光度法测定岩黄连总碱含量为62.5%,用高效液相色谱法测定脱氢卡维汀含量为17.8%。Step 1 Preparation of Licorice root extract: Take 1Kg of Licorice root medicinal material, reflux 3 times with 8L of 60% (V/V) ethanol for 1.5 hours each time, combine the extracts, recover ethanol under reduced pressure and concentrate to liquid medicine The volume is 5L, filtered, and the filtrate is used as the D101 macroporous resin sample solution, and then eluted with 3 times the column volume of 60% ethanol, the eluate is collected, concentrated, and dried to obtain 52 g of Litectin Rhizoma extract, which is analyzed by ultraviolet spectrophotometry The content of total alkaloids in Litectin was determined to be 62.5%, and the content of dehydrocarvetine was determined to be 17.8% by high performance liquid chromatography.
步骤二 配料:分别称取10g的岩黄连提取物,50g的聚乙二醇4000,采用水浴加热方式将聚乙二醇4000加热至熔融后加入岩黄连提取物搅拌均匀得混合液;
步骤三 滴制:将混合液加入于滴丸机的滴制装置内,通过滴头滴入冷凝液中,调整滴丸机的温度控制系统,滴丸机的滴头温度保持在80±10℃左右,液体石蜡为冷凝液,温度保持0±5℃左右;Step 3 Dropping: Add the mixed liquid into the dripping device of the dropping pill machine, drop it into the condensate through the dropper, adjust the temperature control system of the dropping pill machine, and keep the dropper temperature of the dropping pill machine at 80±10°C Around, the liquid paraffin is a condensate, and the temperature is kept at about 0±5°C;
步骤四 擦丸:取出药丸,除去表面冷凝液,干燥即得素滴丸。Step 4 Wipe the pills: Take out the pills, remove the condensed liquid on the surface, and dry to get the Su dropping pills.
结果:丸重为27±1mg,平均每丸中含岩黄连总生物碱2.8mg;每丸含脱氢卡维汀0.80mg。Results: The weight of the pills was 27±1mg, and each pill contained an average of 2.8mg of total alkaloids from Litectinus chinensis; each pill contained 0.80mg of dehydrocarvetine.
实施例2Example 2
步骤一 岩黄连提取物的制备:取岩黄连药材1Kg,每次用6L的50%乙醇回流2次,每次2小时,合并提取液,减压回收乙醇并浓缩至药液为5L,过滤,取滤液为HP-20大孔树脂上样液,解吸附以3倍柱体积的50%乙醇洗脱,收集洗脱液,浓缩,干燥,得到岩黄连提取物49g,用紫外分光光度法测定岩黄连总碱含量为60.5%,用高效液相法测定脱氢卡维汀含量为15.9%。Step 1 Preparation of Litectin extract: Take 1Kg of Litectin, reflux twice with 6L of 50% ethanol for 2 hours each time, combine the extracts, recover ethanol under reduced pressure and concentrate until the liquid is 5L, filter, Get the filtrate as the HP-20 macroporous resin sample solution, desorb and elute with 50% ethanol of 3 times the column volume, collect the eluate, concentrate, and dry to obtain 49g of Litectin Rhizoma extract, and use UV spectrophotometry to determine the amount of rock. The total alkali content of Coptidis Rhizome is 60.5%, and the content of dehydrocarvetine determined by HPLC is 15.9%.
步骤二 配料:分别称取10g的岩黄连提取物,20g的聚乙二醇4000和20g的聚乙二醇6000,采用水浴加热方式将聚乙二醇4000和聚乙二醇6000加热至熔融后加入岩黄连提取物搅拌均匀得混合液;
步骤三 滴制:将混合液加入于滴丸机的滴制装置内,通过滴头滴入冷凝液中,调整滴丸机的温度控制系统,滴丸机的滴头温度保持在80±10℃左右,液体石蜡为冷凝液,温度保持0±5℃左右,滴入冷凝液;Step 3 Dropping: Add the mixed liquid into the dripping device of the dropping pill machine, drop it into the condensate through the dropper, adjust the temperature control system of the dropping pill machine, and keep the dropper temperature of the dropping pill machine at 80±10°C Around, the liquid paraffin is a condensate, the temperature is kept at about 0±5°C, and the condensate is dripped;
步骤四 擦丸:取出药丸,除去表面冷凝液,干燥即得素滴丸。Step 4 Wipe the pills: Take out the pills, remove the condensed liquid on the surface, and dry to get the Su dropping pills.
结果:丸重为27±1mg,平均每丸中含岩黄连总生物碱3.5mg;每丸含脱氢卡维汀0.92mg。Results: The weight of the pills was 27±1mg, and the average content of total alkaloids in each pill was 3.5mg; each pill contained 0.92mg of dehydrocarvetine.
实施例3Example 3
步骤一 岩黄连提取物的制备:取岩黄连药材1Kg,用10L的70%乙醇回流2次,每次1小时,合并提取液,减压回收乙醇并浓缩至药液为5L,过滤后取上清液作为D201大孔树脂上样液,以3倍柱体积的70%乙醇洗脱,收集洗脱液,浓缩,干燥,得到岩黄连提取物59.2g,用紫外分光光度法测定岩黄连总碱含量为55.5%,用高效液相法测定脱氢卡维汀含量为11.6%。Step 1 Preparation of Litectin extract: Take 1Kg of Litectin, reflux twice with 10L of 70% ethanol for 1 hour each time, combine the extracts, recover ethanol under reduced pressure and concentrate until the liquid is 5L, filter and take The supernatant was used as the D201 macroporous resin loading solution, eluted with 70% ethanol of 3 times the column volume, collected the eluate, concentrated, and dried to obtain 59.2g of Litectinum extract, which was determined by UV spectrophotometry for total alkaloids of Litectin The content is 55.5%, and the dehydrocarvetin content is 11.6% as determined by the high performance liquid phase method.
步骤二 配料:分别称取10g的岩黄连提取物,40g的聚乙二醇4000和10g的聚乙二醇6000,采用水浴加热方式将聚乙二醇4000和聚乙二醇6000加热至熔融后加入岩黄连提取物搅拌均匀得混合液;
步骤三 滴制:将混合液加入于滴丸机的滴制装置内,通过滴头滴入冷凝液中,调整滴丸机的温度控制系统,滴丸机的滴头温度保持在80±10℃左右,液体石蜡为冷凝液,温度保持0±5℃左右,混合液滴入冷凝液;Step 3 Dropping: Add the mixed liquid into the dripping device of the dropping pill machine, drop it into the condensate through the dropper, adjust the temperature control system of the dropping pill machine, and keep the dropper temperature of the dropping pill machine at 80±10°C Around, the liquid paraffin is a condensate, the temperature is kept at about 0±5°C, and the mixture drops into the condensate;
步骤四 擦丸:取出药丸,除去表面冷凝液,干燥即得素滴丸。Step 4 Wipe the pills: Take out the pills, remove the condensed liquid on the surface, and dry to get the Su dropping pills.
结果:丸重为27±1mg,平均每丸中含岩黄连总生物碱2.5mg;每丸含脱氢卡维汀0.52mg。Results: The weight of the pills was 27±1mg, and each pill contained an average of 2.5mg of total alkaloids from Litectinus chinensis; each pill contained 0.52mg of dehydrocarvetine.
试验例1 正交试验法优选岩黄连药材的提取工艺Experimental example 1 Orthogonal test method to optimize the extraction process of Litectin chinensis
选择L9(34)正交试验表,对岩黄连药材的提取工艺条件进行优化,因素和水平见表1-1。称取岩黄连粉末50g,按正交试验安排,回流提取,过滤,测定各提取液中总生物碱和脱氢卡维汀的含量。Select the L 9 (3 4 ) orthogonal test table to optimize the extraction process conditions of Litectinus rhizome. The factors and levels are shown in Table 1-1. Weigh 50g of Litectin Rhizoma powder, according to the arrangement of orthogonal experiment, reflux extraction, filter, and measure the content of total alkaloids and dehydrocarvetin in each extract.
表1-1正交试验因素水平表Table 1-1 Orthogonal test factor level table
试验结果test results
以总生物碱和脱氢卡维汀做为评价指标,采用综合评分的方式进行正交工艺优选,总生物碱的得率(mg/g)占比重50%,脱氢卡维汀的得率(mg/g)占比重50%,计算公式如下:综合评分=总生物碱的得率×50%+脱氢卡维汀的得率×50%。结果见表1-2。Taking total alkaloids and dehydrocarvetine as evaluation indicators, the method of comprehensive scoring is used for orthogonal process optimization, the yield of total alkaloids (mg/g) accounts for 50% of the weight, and the yield of dehydrocarvetine (mg/g) accounts for 50% of the weight, and the calculation formula is as follows: comprehensive score=yield of total alkaloids×50%+yield of dehydrocarvetin×50%. The results are shown in Table 1-2.
从表1-2可以看出,岩黄连最佳醇提工艺条件应为A2B3C2D3,即取岩黄连药材粗粉,加10倍量60%乙醇回流提取3次,每次1.5小时。It can be seen from Table 1-2 that the optimal alcohol extraction process condition of Litectinus chinensis should be A 2 B 3 C 2 D 3 , that is, take the coarse powder of Litectinus rhizome and add 10 times the amount of 60% ethanol to reflux extraction for 3 times, each time 1.5 hours.
因为乙醇用量对提取效果影响较小,而以降低成本角度看8倍量比10倍量经济。Because the amount of ethanol has little effect on the extraction effect, and from the perspective of cost reduction, 8 times the amount is more economical than 10 times the amount.
表1-2正交实验结果Table 1-2 Orthogonal experiment results
结论:岩黄连药材用6~10倍60%乙醇回流1~3次,每次1-2小时均能较好的获得提取效果,用8倍60%乙醇回流3次,每次1.5小时为最佳。Conclusion: reflux with 6-10 times 60% ethanol for 1-3 times, each time for 1-2 hours, can obtain good extraction effect, and 8 times 60% ethanol for 3 times, each time for 1.5 hours is the best. good.
试验例2 不同型号的大孔树脂对岩黄连总碱提取物精制效果的筛选Test Example 2 Screening of the refining effect of different types of macroporous resins on the total alkaloids extract of Litectinum Rhizoma
以比吸附量及比洗脱量为指标,对6种型号的大孔树脂进行了筛选。Six types of macroporous resins were screened using the specific adsorption capacity and specific elution capacity as indicators.
上柱液:取岩黄连药材100g,用800mL的60%乙醇回流3次,每次1.5小时,合并提取液,减压回收乙醇并浓缩至药液体积为500mL,过滤后取上清液,作为上柱液。Upper column solution: take 100g of Litectinus chinensis medicinal material, reflux 3 times with 800mL of 60% ethanol, each time for 1.5 hours, combine the extracts, recover ethanol under reduced pressure and concentrate until the volume of the medicinal solution is 500mL, take the supernatant after filtration, and use as Column solution.
大孔树脂对岩黄连总碱提取物精制:湿法装柱(内径1cm×6.4cm),上柱液以2BV/h流速上样,然后再用60%的乙醇洗脱,收集洗脱液,定容至适当体积,测定洗脱液中总生物碱和脱氢卡维汀的含量,计算比吸附量,比洗脱量和洗脱率(洗脱率(%)=比洗脱量/比吸附量×100%),结果见表2。The macroporous resin refines the total alkaloids extract of Litectinum Rhizoma: wet packing column (inner diameter 1cm × 6.4cm), the upper column solution is loaded with a flow rate of 2BV/h, and then eluted with 60% ethanol, and the eluate is collected. Set the volume to an appropriate volume, measure the content of total alkaloids and dehydrocarvetin in the eluent, calculate the specific adsorption capacity, specific elution capacity and elution rate (elution rate (%) = specific elution capacity/ratio Adsorption capacity × 100%), the results are shown in Table 2.
表2各种树脂动态吸附-洗脱性能Table 2 Dynamic adsorption-elution performance of various resins
可以看出,HP-20,D101,DA201三种树脂对总生物碱和脱氢卡维汀均具有较高的比吸附量和洗脱率,其中D101树脂的吸附和洗脱综合性能最佳。HPD-100虽具有较高的比吸附量,但洗脱率低。It can be seen that HP-20, D101, and DA201 resins all have higher specific adsorption capacity and elution rate for total alkaloids and dehydrocarvetin, among which D101 resin has the best comprehensive performance of adsorption and elution. Although HPD-100 has a high specific adsorption capacity, its elution rate is low.
试验例3 选择不同滴丸基质进行组方的实验Experimental example 3 Select different dropping pill bases to carry out the experiment of formulating
实验设计:为增加滴丸中岩黄连总生物碱的溶解度,提高生物利用度,选用水溶性基质,目前用于中药滴丸的水溶性基质主要有聚乙二醇类(PEG)、聚氧乙烯40、硬脂酸钠、甘油明胶等。基质与主药不能发生反应,对人体无害,另外还要熔点比较低,易熔融,骤冷能很快凝固成固体,且加入药物后这一性质不变。在此,主要选择具有良好分散力和较大内聚力的PEG来作为基质。Experimental design: In order to increase the solubility of total alkaloids of Litectinus chinensis in dripping pills and improve bioavailability, water-soluble substrates were selected. Currently, the water-soluble substrates used in Chinese medicine dripping pills mainly include polyethylene glycol (PEG), polyoxyethylene 40. Sodium stearate, glycerin gelatin, etc. The matrix and the main drug cannot react and are harmless to the human body. In addition, the melting point is relatively low, easy to melt, and can be quickly solidified into a solid when quenched, and this property remains unchanged after adding the drug. Here, PEG with good dispersion and greater cohesion is mainly selected as the matrix.
聚乙二醇(Polyethyeneglycol,PEG)系氧化乙烯或环氧乙烷与水加成缩聚的混合物,分子量200-25000不等。拟定辅料种类主要为PEG4000、PEG6000或两者不同比例的混合物,并制备空白基质滴丸进行筛选,筛选结果见表3。Polyethylene glycol (Polyethyeneglycol, PEG) is a mixture of ethylene oxide or ethylene oxide and water addition polycondensation, molecular weight ranging from 200-25000. The proposed excipients are mainly PEG4000, PEG6000 or a mixture of the two in different proportions, and a blank matrix dropping pill is prepared for screening. The screening results are shown in Table 3.
表3滴丸基质筛选结果Table 3 Dropping Pill Matrix Screening Results
由表3可知,PEG4000∶PEG6000在重量比为5~0∶0~5范围内,均可做为滴丸基质,其中优选PEG4000∶PEG6000的重量比为4∶1或3∶2或1∶1,尤以PEG4000∶PEG6000的重量比为4∶1为最佳。It can be seen from Table 3 that PEG4000: PEG6000 can be used as a drop pill base in the range of 5-0: 0-5 in weight ratio, and the preferred weight ratio of PEG4000: PEG6000 is 4: 1 or 3: 2 or 1: 1 , especially the weight ratio of PEG4000:PEG6000 is 4:1 is the best.
实施例4 滴丸包糖衣例Example 4 Dropping pills coated with sugar
(1)糖衣包衣液处方:(1) Prescription of sugar coating solution:
65% 糖浆 1ml65% syrup 1ml
15% 明胶液 0.2ml15% gelatin solution 0.2ml
滑石粉 2.4gTalc powder 2.4g
川蜡 0.002gSichuan wax 0.002g
(2)糖衣包衣方法:将65%糖浆1ml、15%明胶液0.2ml混合,搅拌均匀,即得胶糖浆。将实施例1所得岩黄连的素滴丸置于包衣锅内,预热至35-40℃。先加入0.06ml胶糖浆,再加入0.24g滑石粉,热风干燥,包衣3-4层后,改加入0.12ml胶糖浆,滑石粉逐渐减至最少为0.1g,最后一次只加胶糖浆,不加滑石粉,共包8层-10层糖衣。滴丸干燥后停止包衣锅转动,吹冷风使滴丸温度降至室温后,加入0.002g川蜡粉,旋转包蜡衣至滴丸光亮圆滑,蜡衣均匀,滴丸每丸29±1mg。(2) Sugar coating method: mix 1 ml of 65% syrup and 0.2 ml of 15% gelatin solution, and stir evenly to obtain gum syrup. Put the plain dropping pills of rhizoma rhizome obtained in Example 1 in the coating pan, and preheat to 35-40°C. First add 0.06ml of gum syrup, then add 0.24g of talcum powder, dry with hot air, after coating 3-4 layers, add 0.12ml of gum syrup, gradually reduce the talcum powder to a minimum of 0.1g, and only add gum syrup for the last time. Add talcum powder, and wrap 8-10 layers of icing in total. After the dropping pills are dried, stop the rotation of the coating pan, blow the cold wind to reduce the temperature of the dropping pills to room temperature, add 0.002g of Sichuan wax powder, and rotate the wax coating until the dropping pills are bright and smooth, and the wax coating is uniform. Each dropping pill is 29±1mg.
实施例5 滴丸包薄膜衣例Example 5 Dropping Pills with Film Coating Example
(1)薄膜衣包衣液处方:(1) Prescription of film coating solution:
羟丙基甲基纤维素 2gHydroxypropyl methylcellulose 2g
滑石粉 2gTalc powder 2g
二氧化钛 0.2gTitanium dioxide 0.2g
甘油 1mlGlycerin 1ml
70%乙醇 100ml70% ethanol 100ml
(2)包衣方法:将羟丙基甲基纤维素2g加入100mL 70%乙醇,浸泡溶解后,加入过100目筛的滑石粉和二氧化钛,再加入甘油,充分搅拌均匀,100目筛过滤后,即得包衣液。包衣液在喷出以前先振摇均匀。将实施例1所得岩黄连的素滴丸置于包衣锅内,预热至40℃,喷包衣液适量,用40℃热风与冷风交替干燥,包衣锅转速为25~45转/分,喷液时可低转速,干燥时可高转速。反复喷液干燥,直至滴丸重增加2%~4%。包衣后,置干燥器中干燥24h以上,即得包衣滴丸。(2) Coating method: add 2 g of hydroxypropyl methylcellulose to 100 mL of 70% ethanol, soak and dissolve, add talcum powder and titanium dioxide passed through a 100-mesh sieve, then add glycerin, stir well, and filter through a 100-mesh sieve , to obtain the coating solution. Shake the coating solution evenly before spraying. Put the plain dripping pills of Litectin chinensis obtained in Example 1 in a coating pan, preheat to 40°C, spray an appropriate amount of coating liquid, and dry them alternately with hot air and cold air at 40°C, and the rotating speed of the coating pan is 25-45 rpm , It can be rotated at low speed when spraying liquid, and high speed can be used when drying. Repeated spray drying until the weight of the dropping pills increases by 2% to 4%. After coating, dry in a desiccator for more than 24 hours to obtain the coated dropping pills.
试验例4 正交试验优化处方及滴制工艺Test Example 4 Orthogonal test to optimize prescription and dripping process
岩黄连提取物的制备及滴丸滴制的工艺条件同实施例1。The preparation of Litectin Rhizoma extract and the process conditions of dropping pills are the same as in Example 1.
在单因素考察试验结果的基础上,进行正交设计,以筛选滴丸制备的最佳工艺及最佳处方,因素和水平见表4-1。以滴制的难易程度、滴丸的圆整度、硬度、外观、重量差异及溶散时限为指标,以5分制进行评分,见表4-2,综合评分计算公式为:总分=a+b+c+d+e+f。On the basis of the single factor investigation test results, an orthogonal design was carried out to screen the best technology and prescription for the preparation of dripping pills. The factors and levels are shown in Table 4-1. Taking the difficulty of dripping, the roundness, hardness, appearance, weight difference and dissolution time limit of the dropping pills as indicators, the scores are scored on a 5-point system, see Table 4-2. The formula for calculating the comprehensive score is: total score = a+b+c+d+e+f.
正交实验结果见表4-3,可得出岩黄连滴丸最佳制备工艺条件应为A2B1C2D3,即药物与基质配比为1∶5,70℃的保温温度,冷凝温度为0℃,滴速为30滴/min。The results of the orthogonal experiment are shown in Table 4-3. It can be concluded that the optimal preparation process conditions of Yanhuanglian dripping pills should be A 2 B 1 C 2 D 3 , that is, the ratio of drug to matrix is 1:5, and the holding temperature is 70°C. The condensation temperature is 0°C, and the drop rate is 30 drops/min.
表4-1正交试验因素水平表Table 4-1 Orthogonal test factor level table
表4-2评分表Table 4-2 Grading Form
表4-3正交实验结果Table 4-3 Orthogonal experiment results
试验例5 岩黄连滴丸和片剂的体外溶出度比较Test Example 5 The in vitro dissolution rate comparison of Yanhuanglian dripping pills and tablets
滴丸:取实施例1的样品Dropping pill: get the sample of embodiment 1
片剂:制备方法如下:取岩黄连总生物碱、淀粉及糖粉以60目筛混合过筛2次,加乙醇(45%)做湿润剂拌和制成软材,然后通过16目筛制粒,在60℃下干燥1h,干粒再通过16目筛,加干淀粉5%做崩解剂与0.5%硬脂酸镁做润滑剂,充分混合后压片。制得片剂的重量为100mg/片,其中总生物碱含量为15mg,脱氢卡维汀含量为4.8mg。Tablet: the preparation method is as follows: take the total alkaloids of Litectinus chinensis, starch and powdered sugar, mix and sieve twice with a 60-mesh sieve, add ethanol (45%) as a wetting agent and stir to make a soft material, and then pass through a 16-mesh sieve to granulate , dried at 60°C for 1 hour, the dry granules passed through a 16-mesh sieve, added 5% dry starch as a disintegrant and 0.5% magnesium stearate as a lubricant, mixed thoroughly and then pressed into tablets. The weight of the prepared tablet is 100 mg/tablet, wherein the total alkaloid content is 15 mg, and the dehydrocarvetine content is 4.8 mg.
测试方法Test Methods
参照《中国药典》2005版二部附录XC选用小杯法进行实验。溶出介质采用250mL脱气的0.1N盐酸,温度控制在37℃,转速50r/min,供试品进入释放池瞬间开始计时,分别在不同时间点取样4mL(同时补充等温等体积的溶出介质),用0.45μm微孔滤膜立即过滤,续滤液在346nm处测定吸光度。代入回归方程计算岩黄连总生物碱含量,并计算累积溶出百分率。Refer to the second appendix XC of "Chinese Pharmacopoeia" 2005 edition and choose the small cup method to carry out the experiment. The dissolution medium uses 250mL degassed 0.1N hydrochloric acid, the temperature is controlled at 37°C, and the rotation speed is 50r/min. The time is started as soon as the test product enters the release cell, and 4mL samples are taken at different time points (while adding isothermal and equal volume dissolution medium), Filter immediately with a 0.45 μm microporous membrane, and then measure the absorbance of the filtrate at 346 nm. Substitute into the regression equation to calculate the total alkaloid content of Litectinus chinensis, and calculate the cumulative dissolution percentage.
试验结果 如表5所示The test results are shown in Table 5
表5岩黄连滴丸与岩黄连片的溶出度比较Table 5 Comparison of the dissolution rates of Yanhuanglian dripping pills and Yanhuanglian tablets
结论:岩黄连滴丸与片剂相比,溶出速度快,累积溶出量高。Conclusion: Compared with tablets, Yanhuanglian dripping pills have a faster dissolution rate and a higher cumulative dissolution amount.
试验例6 岩黄连滴丸与片剂的药代动力学研究Test Example 6 Pharmacokinetic study of Yanhuanglian dripping pills and tablets
实验材料:岩黄连滴丸和岩黄连片,同试验例5,Experimental materials: Yanhuanglian dripping pills and Yanhuanglian tablets, same as test example 5,
将岩黄连滴丸和岩黄连片剂分别制成混悬水溶液,灌胃给与SD大鼠,给药剂量为20mg/kg。灌胃给药后0,10,20,30,60,120,180,240,300,360,480,540min眼眶取血,分离血浆后,采用HPLC-MS/MS法测定血浆样品中的脱氢卡维汀的含量,分别绘制口服给与滴丸或片剂后脱氢卡维汀的血药浓度-时间曲线(如附图1所示),计算药代动力学参数,结果见表6。Yanhuanglian dripping pills and Yanhuanglian tablets were made into suspension aqueous solutions, and given to SD rats by intragastric administration at a dose of 20 mg/kg. At 0, 10, 20, 30, 60, 120, 180, 240, 300, 360, 480, 540 minutes after intragastric administration, blood was taken from the orbit, and after the plasma was separated, the dehydrogenation in the plasma sample was determined by HPLC-MS/MS method The content of Carvetine draws the plasma concentration-time curve (as shown in Figure 1) of dehydrocarvetine after oral administration respectively of drop pill or tablet, calculates pharmacokinetic parameter, the results are shown in Table 6.
表6岩黄连滴丸和片剂的主要药代动力学参数The main pharmacokinetic parameters of table 6 Yanhuanglian dripping pills and tablets
与岩黄连片剂相比,*P<0.05Compared with Yanhuanglian tablet, * P<0.05
结果显示,岩黄连滴丸的生物利用度较岩黄连片剂相比有显著提高,AUC0-∞可提高近一倍,最高血药浓度是片剂的3.5倍,达峰时间从片剂的75min缩短至50min。The results show that the bioavailability of Yanhuanglian dripping pills is significantly improved compared with Yanhuanglian tablets, AUC 0-∞ can be nearly doubled, the highest blood concentration is 3.5 times that of tablets, and the peak time is from the tablet's 75min shortened to 50min.
结论:本发明所制的岩黄连滴丸具有生物利用度高、快速释药的特点。Conclusion: Yanhuanglian dripping pills prepared by the present invention have the characteristics of high bioavailability and rapid drug release.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101926637A CN101669998B (en) | 2009-09-24 | 2009-09-24 | Corydalis saxicola pill and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101926637A CN101669998B (en) | 2009-09-24 | 2009-09-24 | Corydalis saxicola pill and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101669998A CN101669998A (en) | 2010-03-17 |
CN101669998B true CN101669998B (en) | 2011-08-31 |
Family
ID=42017555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101926637A Expired - Fee Related CN101669998B (en) | 2009-09-24 | 2009-09-24 | Corydalis saxicola pill and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101669998B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102600247B (en) * | 2012-04-11 | 2014-02-05 | 宁波德沃生物科技有限公司 | Corydalis saxicola bunting alkaloid extract and preparation method thereof |
CN103764158B (en) * | 2012-06-25 | 2020-04-14 | 佛山市顺德区合生源医药研发有限公司 | Preparation for resisting tachyarrhythmia and preparation method thereof |
CN105596457A (en) * | 2016-03-01 | 2016-05-25 | 河南中医学院 | Traditional Chinese medicine preparation heart-fire clearing and restlessness relieving tablets for preventing and treating excess-heat anxiety disorder |
CN114191467B (en) * | 2021-12-06 | 2023-06-06 | 广西师范大学 | A method for extracting high-purity alkaloids from Litectin |
-
2009
- 2009-09-24 CN CN2009101926637A patent/CN101669998B/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101669998A (en) | 2010-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5675839B2 (en) | Pharmaceutical composition comprising sunflower extract, method for its preparation and use | |
JP6091651B2 (en) | Pharmaceutical composition for treating headache and method for preparing the same | |
JP2016539955A (en) | Drug composition, method for producing the same, and use | |
EP1930020A1 (en) | Chinese medicinal compositions for treating headache, formulations and processes for preparation thereof | |
CN104825615B (en) | A kind of preparation method and its method of quality control of huanglian jiedu decoction granule | |
CN101669998B (en) | Corydalis saxicola pill and preparation method thereof | |
CN102771593A (en) | Ampelopsis grossedentata preparation for reducing blood sugar, blood lipid and blood pressure and its preparation method | |
KR20160117425A (en) | Solid dispersion containing desmodium styracifolium (osb.) merr. flavonoids, method of preparing same, and use thereof | |
WO2008145064A1 (en) | The method for a sequoyitol-containing extract obtaining from the genus of trifolium, sobyean and ginkgo biloba and use thereof | |
CN104415097A (en) | Sublingual administration preparation containing total alkaloids in lotus leaf or lotus plumule, and use thereof | |
CN101757058B (en) | A kind of total flavonoid extract of hollyhock flower, its preparation and application | |
CN103271978B (en) | Ginkgo leaf compound preparation for resisting oxygen deprivation and glucose deprivation and treating altitude sickness | |
CN108619374B (en) | Ginseng and fritillary bulb composition as well as preparation method and application thereof | |
CN100490785C (en) | Freeze-dried 'Shengmai' powder for injection and its preparing process | |
CN100455314C (en) | Medication for treating cough | |
CN100478001C (en) | Tribulus terrestris extraction and its preparation method and use | |
CN103127235B (en) | Preparation method of medicine having liver protection and liver fibrosis effects | |
CN108261435A (en) | A kind of Orychophragmus violaceus alkaloids extract and its application in liver protection product is prepared | |
CN102406897B (en) | Xingnaojing solid medicinal composition and preparation method thereof | |
CN112402515A (en) | Chinese medicinal extract containing insect medicine and preparation method of preparation thereof | |
CN101244124A (en) | Preparation method and application of active part of mulberry leaves | |
CN100482267C (en) | Preparation for diabetes and its making method | |
CN1256131C (en) | Chinese traditional medicine preparation Qimaishen for treating viral myocarditis and its manufacturing method | |
CN100522146C (en) | Preparation method of Chinese traditional medicine slow release preparation for treating coronary heart disease and angina pectoris | |
CN100350899C (en) | Diphase capsule of red sage root for coronary heart disease and preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110831 Termination date: 20190924 |